Table 2.
F-statistics, means and standard deviations for the four vaccine-hesitant groups.
| F (df1, df2) | Within one month (n = 169) | Within two months (n = 76) | Within three months (n = 53) | Three or more months (n = 202) | |
|---|---|---|---|---|---|
| Knowledge of BioNTech | 2.11 (3, 490) |
3.18 (0.70) | 3.09 (0.70) | 3.09 (0.66) | 2.96 (0.66) |
| Knowledge of Sinovac | 2.49 (3, 490) |
3.10 (0.75) | 3.05 (0.73) | 2.92 (0.81) | 2.87 (0.65) |
| Perceived susceptibility to infection | 0.58 (3, 490) |
2.60 (0.77) |
2.68 (0.75) |
2.68 (0.70) |
2.71 (0.71) |
| Risks from coronavirus | 1.45 (3, 490) |
42.45 (19.10) |
41.36 (20.27) |
44.95 (20.66) |
45.69 (21.12) |
| Risks from vaccination in general | 3.03* (3, 490) |
35.62a (20.37) |
36.62 (17.39) | 37.99 (18.40) | 41.60a (20.08) |
| Benefits of BioNTech | 12.06*** (3, 490) | 3.62b (0.52) | 3.49c (0.47) | 3.54d (0.56) | 3.32b,c,d (0.50) |
| Benefits of Sinovac | 4.98** (3, 490) |
2.87e,f (0.83) |
2.59e (0.64) |
2.74 (0.75) |
2.61f (0.73) |
| Risks from BioNTech | 1.05 (3, 490) |
3.34 (0.58) | 3.22 (0.48) | 3.35 (0.61) | 3.36 (0.57) |
| Risks from Sinovac | 3.18* (3, 490) |
3.17 (0.71) |
3.11 (0.50) |
3.38 (0.66) |
3.34 (0.67) |
Notes. * p <.05. ** p <.01. *** p <.001. a–f Mean is statistically different from the mean of the relevant comparison group indicated by the same letter at a 0.05 significance level. Standard deviations are reported in the brackets. All comparisons controlled for gender, age, education, income, party identification and health status.